Dr David Thomson is a Consultant Clinical Oncologist, appointed as Clinical Director of the Greater Manchester Head and Neck Cancer Pathway Board, prioritising the improvement of survival outcomes and long-term quality of life for patients treated for head and neck cancer.

Dr Thomson qualified from Oxford University Medical School in 2004 with a First-Class honours intercalated degree in Physiological Sciences, later undertaking a research Fellowship at the University of Manchester with attachment to the University of Pennsylvania in the United States and was awarded a Doctor of Medicine (MD) research degree in 2015. His interest in medical education lead him to completing a Postgraduate Certificate in Medical Education with Distinction in 2014 and the following year, was appointed Consultant Clinical Oncologist at The Christie and Honorary Senior Lecturer at The University of Manchester, specialising in the treatment of head and neck cancer.

Dr Thomson is a member of the National Cancer Research (NCRI) group for head and neck cancer, research lead for the head and neck team at The Christie, Deputy Chief Investigator for the UK phase 3 NIMRAD trial (assessing the benefit of hypoxia modification using nimorazole with radiotherapy in those unsuitable for concurrent chemotherapy), Principal Investigator for a number of portfolio studies, Proton Beam Therapy national panel member and policy lead for head and neck cancer, member of the Clinical Innovation Board and clinical lead for electronic patient reported outcomes in head and neck cancer at The Christie.

• Radiotherapy
• Chemotherapy

• Clinical oncology
• Cancer care
• Head & neck cancers